AU2017315952B2 - RNAi constructs for inhibiting ASGR1 expression and methods of use thereof - Google Patents

RNAi constructs for inhibiting ASGR1 expression and methods of use thereof Download PDF

Info

Publication number
AU2017315952B2
AU2017315952B2 AU2017315952A AU2017315952A AU2017315952B2 AU 2017315952 B2 AU2017315952 B2 AU 2017315952B2 AU 2017315952 A AU2017315952 A AU 2017315952A AU 2017315952 A AU2017315952 A AU 2017315952A AU 2017315952 B2 AU2017315952 B2 AU 2017315952B2
Authority
AU
Australia
Prior art keywords
seq
sequence
rnai construct
antisense
sense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017315952A
Other languages
English (en)
Other versions
AU2017315952A1 (en
Inventor
John Gordon Allen
Kaustav Biswas
Yuan Cheng
Oliver HOMANN
Yang Li
Leslie P. Miranda
Justin K. Murray
Chawita NETIROJJANAKUL
Michael Ollmann
Bin Wu
Oh Kyu YOON
Jun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2017315952A1 publication Critical patent/AU2017315952A1/en
Application granted granted Critical
Publication of AU2017315952B2 publication Critical patent/AU2017315952B2/en
Priority to AU2024201349A priority Critical patent/AU2024201349A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2017315952A 2016-08-26 2017-08-25 RNAi constructs for inhibiting ASGR1 expression and methods of use thereof Active AU2017315952B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024201349A AU2024201349A1 (en) 2016-08-26 2024-02-29 RNAi constructs for inhibiting ASGR1 expression and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380216P 2016-08-26 2016-08-26
US62/380,216 2016-08-26
PCT/US2017/048757 WO2018039647A1 (en) 2016-08-26 2017-08-25 Rnai constructs for inhibiting asgr1 expression and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024201349A Division AU2024201349A1 (en) 2016-08-26 2024-02-29 RNAi constructs for inhibiting ASGR1 expression and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2017315952A1 AU2017315952A1 (en) 2019-03-14
AU2017315952B2 true AU2017315952B2 (en) 2023-11-30

Family

ID=59846644

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017315952A Active AU2017315952B2 (en) 2016-08-26 2017-08-25 RNAi constructs for inhibiting ASGR1 expression and methods of use thereof
AU2024201349A Pending AU2024201349A1 (en) 2016-08-26 2024-02-29 RNAi constructs for inhibiting ASGR1 expression and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024201349A Pending AU2024201349A1 (en) 2016-08-26 2024-02-29 RNAi constructs for inhibiting ASGR1 expression and methods of use thereof

Country Status (10)

Country Link
US (2) US10870856B2 (cg-RX-API-DMAC7.html)
EP (1) EP3504333A1 (cg-RX-API-DMAC7.html)
JP (3) JP7082610B2 (cg-RX-API-DMAC7.html)
AR (1) AR110629A1 (cg-RX-API-DMAC7.html)
AU (2) AU2017315952B2 (cg-RX-API-DMAC7.html)
CA (1) CA3034463C (cg-RX-API-DMAC7.html)
MX (2) MX2019002271A (cg-RX-API-DMAC7.html)
TW (1) TW201823461A (cg-RX-API-DMAC7.html)
UY (1) UY37376A (cg-RX-API-DMAC7.html)
WO (1) WO2018039647A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
SI3661562T1 (sl) 2017-08-04 2025-01-31 Amgen Inc. Postopek konjugiranja CYS-MABS
WO2019079294A1 (en) * 2017-10-17 2019-04-25 Arrowhead Pharmaceuticals, Inc. RNAI-BASED AGENTS AND COMPOSITIONS FOR INHIBITING ASIALOGLYCOPROTEIN RECEPTOR 1 RECEPTOR 1
AU2018360697A1 (en) * 2017-11-01 2020-05-14 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
KR102798620B1 (ko) * 2018-06-07 2025-04-22 암젠 인크 단백질-폴리뉴클레오티드 접합체에 대한 검출 검정
EP3894554A1 (en) * 2018-12-10 2021-10-20 Amgen Inc. Chemically-modified rnai constructs and uses thereof
SG11202113112WA (en) * 2019-05-30 2021-12-30 Amgen Inc Rnai constructs for inhibiting scap expression and methods of use thereof
EP3990465A1 (en) 2019-06-25 2022-05-04 Amgen Inc. Purification methods for carbohydrate-linked oligonucleotides
US20230314417A1 (en) 2020-03-23 2023-10-05 Amgen Inc. Monoclonal antibodies to chemically-modified nucleic acids and uses thereof
CN111705063B (zh) * 2020-06-02 2023-08-08 成都中科奥格生物科技有限公司 Asgr1突变基因及其在制备哺乳动物肝损伤敏感模型中的应用
WO2024046297A1 (zh) * 2022-09-02 2024-03-07 北京福元医药股份有限公司 抑制去唾液酸糖蛋白受体基因表达的siRNA、其缀合物和药物组合物及用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031844A1 (en) * 2002-11-14 2007-02-08 Anastasia Khvorova Functional and hyperfunctional siRNA

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
AU723163B2 (en) 1995-06-07 2000-08-17 Tekmira Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
DE69834038D1 (de) 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
ATE237312T1 (de) 1998-07-20 2003-05-15 Protiva Biotherapeutics Inc In liposomen verkapselte nukleinsäurekomplexe
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1549352A4 (en) 2002-05-06 2005-07-27 Nucleonics Inc METHOD OF DISTRIBUTING NUCLEIC ACIDS
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
DK1620544T3 (en) 2003-04-17 2019-01-14 Alnylam Pharmaceuticals Inc MODIFIED iRNA AGENTS
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
EP2465534B1 (en) * 2004-06-10 2017-03-29 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN1300312C (zh) 2004-08-23 2007-02-14 中国人民解放军军事医学科学院放射与辐射医学研究所 靶向去唾液酸糖蛋白受体的抗乙型肝炎病毒反义寡核苷酸的结构和用途
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JP2007285749A (ja) * 2006-04-13 2007-11-01 Kitasato Gakuen インフルエンザ感染検査薬及び検査方法
KR101133799B1 (ko) * 2006-08-18 2012-04-24 에프. 호프만-라 로슈 아게 폴리뉴클레오타이드의 생체내 전달을 위한 다가접합체
JP4889437B2 (ja) * 2006-10-16 2012-03-07 オリンパス株式会社 微弱光撮像装置
JP2008241447A (ja) * 2007-03-27 2008-10-09 Fujifilm Corp 画像読取装置及び画像読取方法
US8877917B2 (en) 2007-04-23 2014-11-04 Alnylam Pharmaceuticals, Inc. Glycoconjugates of RNA interference agents
JP5265140B2 (ja) * 2007-06-14 2013-08-14 学校法人日本医科大学 卵巣癌の検出方法及び検出用キット
CA2910760C (en) 2007-12-04 2019-07-09 Muthiah Manoharan Targeting lipids
JP2010271078A (ja) * 2009-05-19 2010-12-02 Mcbi:Kk 認知機能障害疾患を含む精神疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患を含む精神疾患の検出方法
US20130024961A1 (en) 2009-12-01 2013-01-24 Christopher Burlak Methods of Modulating Thrombocytopenia and Modified Transgenic Pigs
KR101870915B1 (ko) * 2011-04-08 2018-06-25 유니버시티 오브 레스터 Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
WO2012177639A2 (en) * 2011-06-22 2012-12-27 Alnylam Pharmaceuticals, Inc. Bioprocessing and bioproduction using avian cell lines
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
JP6694382B2 (ja) 2013-06-21 2020-05-13 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 標的核酸を調節するための組成物および方法
WO2016170348A2 (en) * 2015-04-22 2016-10-27 Mina Therapeutics Limited Sarna compositions and methods of use
AU2016332900C1 (en) * 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070031844A1 (en) * 2002-11-14 2007-02-08 Anastasia Khvorova Functional and hyperfunctional siRNA

Also Published As

Publication number Publication date
US11732266B2 (en) 2023-08-22
JP2019524151A (ja) 2019-09-05
AU2017315952A1 (en) 2019-03-14
MX2024009873A (es) 2024-08-20
US20210108212A1 (en) 2021-04-15
CA3034463A1 (en) 2018-03-01
AR110629A1 (es) 2019-04-17
MX2019002271A (es) 2019-06-20
TW201823461A (zh) 2018-07-01
JP7082610B2 (ja) 2022-06-08
CA3034463C (en) 2025-09-16
UY37376A (es) 2018-03-23
JP2024019733A (ja) 2024-02-09
JP7472180B2 (ja) 2024-04-22
JP2022060357A (ja) 2022-04-14
EP3504333A1 (en) 2019-07-03
AU2024201349A1 (en) 2024-04-11
US20190309306A1 (en) 2019-10-10
US10870856B2 (en) 2020-12-22
WO2018039647A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
AU2017315952B2 (en) RNAi constructs for inhibiting ASGR1 expression and methods of use thereof
AU2015252858C1 (en) Compositions and methods for modulating Complement Factor B expression
TWI659040B (zh) 用於抑制ｂ型肝炎病毒基因表現之組合物及方法
KR101770435B1 (ko) 자연 안티센스 전사체가 아포리포단백질-ａ1로 억제에 의해 아포리포단백-ａ1 관련된 질환의 치료
KR101835889B1 (ko) 지질 수송 및 대사 유전자에 대한 천연 안티센스 전사체의 억제에 의해 지질 수송 및 대사 유전자 관련된 질환의 치료
CN110234326B (zh) 用于抑制因子xii基因表达的组合物和方法
JP2021072843A (ja) アポリポタンパク質ｃ−ｉｉｉ（ａｐｏｃ３）の発現を阻害するための組成物及び方法
JP2023537943A (ja) ＭＡＲＣ１発現を阻害するためのＲＮＡｉコンストラクト及び方法
AU2019284028A1 (en) Compositions and methods for modulating pkk expression
IL265410A (en) Preparations and methods for inhibiting the expression of alas1 gene
KR20160118346A (ko) 케토헥소키나제(ＫＨＫ) ｉＲＮＡ 조성물 및 그의 사용 방법
TW200911989A (en) RNAi inhibition of alpha-ENaC expression
KR20180051550A (ko) 프로그램된 세포사 1 리간드 1 (PD-L1) iRNA 조성물 및 그의 사용 방법
JP2024530647A (ja) 標的ｒｎａ送達のための組成物および方法
NZ718995A (en) Compositions and methods for inhibiting expression of the alas1 gene
KR20240004092A (ko) Hsd17b13 발현을 억제하기 위한 rnai 작제물 및 이의 사용 방법
KR20110081337A (ko) 안티센스 올리고누클레오티드에 의한 ｔｏｌｌ―유사 수용체 4 발현의 조절
IL310180A (en) products and preparations
KR20110081338A (ko) 안티센스 올리고누클레오티드에 의한 ｔｏｌｌ―유사 수용체 5 발현의 조절
TW202435897A (zh) 用於治療遺傳性ｈｆｅ血色沉著病之反義寡核苷酸
KR20240033228A (ko) Mst1 관련 질환 및 장애의 치료
KR20250119645A (ko) Ttr 발현을 억제하기 위한 rnai 구성체 및 이의 사용 방법
CN119300841A (zh) 用于抑制scap表达的rnai构建体及其使用方法
JP2025512771A (ja) ＰＮＰＬＡ３発現を阻害するためのＲＮＡｉコンストラクト及びその使用方法
RU2842959C2 (ru) Композиции и способы ингибирования экспрессии гена alas1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)